share_log

Prelude Therapeutics | 10-K: FY2022 Annual Report

SEC ·  Mar 15, 2023 20:53
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.